[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371923-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371923-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","characterizing-heterogeneous-cis-regulatory-elements-in-gene-regulatory-programs-associated-with-breast-cancer","Characterizing heterogeneous cis-regulatory elements in gene regulatory programs associated with breast cancer","","Cis-regulatory elements (CREs) drive oncogene expression and malignant phenotypes, yet cancer’s clinical and pathological diversity cannot be explained by gene expression alone because CRE heterogeneity is central. Characterizing cancer-associated CREs remains difficult, motivating single-cell epigenomic profiling of clinical breast cancer specimens. Using scATAC-seq on prospectively collected samples, the study maps candidate CREs and their enhancer–promoter relationships across tumor and microenvironment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/characterizing-heterogeneous-cis-regulatory-elements-in-gene-regulatory-programs-associated-with-breast-cancer/371923/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/characterizing-heterogeneous-cis-regulatory-elements-in-gene-regulatory-programs-associated-with-breast-cancer/371923.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is CRE heterogeneity important in breast cancer?","Question",{"text":63,"@type":64},"CRE heterogeneity helps explain why clinical and pathological diversity in cancer cannot be accounted for by gene expression alone, linking CRE variation to malignant phenotypes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What data and experimental approach were used to map candidate CREs?",{"text":68,"@type":64},"The study performed scATAC-seq on 38 prospectively collected breast cancer samples to profile chromatin accessibility and identify candidate cis-regulatory elements.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the researchers characterize regulatory heterogeneity?",{"text":72,"@type":64},"By identifying cluster-specific differentially accessible candidate CREs and constructing an enhancer–promoter network, the study showed that enhancer accessibility differs within and between tumors and across the tumor ecosystem.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371923,1790219007,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Hori etal. Genome Medicine (2025) 17:145 [https://doi.org/10.1186/s13073-025-01562-1](https://doi.org/10.1186/s13073-025-01562-1)  \nGenome Medicine  \n RESEARCH Open Access  \nCharacterizing heterogeneous cis-regulatory   elements in gene regulatory programs associated with breast cancer  \nChisa Hori1,2†, Kohei Kumegawa3*†, Sumito Saeki1,4, Yoko Takahashi4, Liying Yang1, Tomoyoshi Nakadai 1, Kazutaka Otsuji3, ChikakoTakahata4, Yukinori Ozaki5, Natsue Uehiro4, Yurie Haruyama4, Tomo Osako6, Toshimi Takano5, Seiichi Mori7, Tetsuo Noda8, Satoshi Fujii2, Shinji Ohno9, Takayuki Ueno4 and Reo Maruyama1,3*  \nAbstract  \nBackground Cis-regulatory elements (CREs) control oncogene expression and malignant phenotypes. The high clinicopathological heterogeneity of cancer cannot be explained by gene expression alone, being attributed to CRE heterogeneity. However, characterizing cancer-associated CREs is challenging. To address this issue, we performed a single-cell epigenomic analysis of clinical specimens.  \nMethods To map the multicellular ecosystem of breast cancer (BC) and identify candidate CREs (cCREs), we performed a single-cell assay for transposase-accessible chromatin with sequencing (scATAC-seq) of 38 prospectively collected BC samples with various clinicopathological characteristics.  \nResults First, we performed single-cell chromatin accessibility profiling of a high-quality set of 22,775 cells from BC samples. Cells were annotated using marker gene accessibility and integration with existing single-cell RNA sequencing data. The chromatin accessibility patterns exhibited by cancer cells were consistent with the clinicopathological features of each tumor. We identified 224,585 cCREs across the BC ecosystem. By identifying cluster-specific differentially accessible cCREs (DA-cCREs) and constructing a putative enhancer–promoter network, we mapped the cis-regulatory landscape for cancer cells and the tumor microenvironment. The accessibility of putative enhancers targeting the same gene differed within or between tumors, highlighting intra-and inter-cis-regulatory tumor heterogeneity. Conclusions This study provides a valuable resource for future epigenetic research on BC and highlights the diverse regulatory landscape within or among tumor(s), suggesting that cCREs regulate intra-and intertumor heterogeneity. Keywords Cis-regulatory element, Single-cell ATAC-seq, Breast cancer, Tumor heterogeneity  \n†Chisa Hori and Kohei Kumegawa contributed equally to this work.  \n*Correspondence:  \nKohei Kumegawa [kohei.kumegawa@jfcr.or.jp](kohei.kumegawa@jfcr.or.jp)[ ](kohei.kumegawa@jfcr.or.jp)Reo Maruyama [reo.maruyama@jfcr.or.jp](reo.maruyama@jfcr.or.jp)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nHori etal. Genome Medicine (2025) 17:145  \nBackground  \nConsortium studies, such as ","cbCaihPNxM97U1fo","https://ap.wps.com/l/cbCaihPNxM97U1fo","pdf",10325491,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"Why is CRE heterogeneity important in breast cancer?\",\"answer\":\"CRE heterogeneity helps explain why clinical and pathological diversity in cancer cannot be accounted for by gene expression alone, linking CRE variation to malignant phenotypes.\"},{\"question\":\"What data and experimental approach were used to map candidate CREs?\",\"answer\":\"The study performed scATAC-seq on 38 prospectively collected breast cancer samples to profile chromatin accessibility and identify candidate cis-regulatory elements.\"},{\"question\":\"How did the researchers characterize regulatory heterogeneity?\",\"answer\":\"By identifying cluster-specific differentially accessible candidate CREs and constructing an enhancer–promoter network, the study showed that enhancer accessibility differs within and between tumors and across the tumor ecosystem.\"}]","Characterizing heterogeneous cis-regulatory elements in gene regulatory programs associated with breast cancer | PDF",1790193233,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb881de032d7e3da2d972e15b3fb1756.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81d6b5815f0e838f83ac3c08472b39d8.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/085ed3fd59d4844a881008d65171e6a8.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f69283437aae2637e7b0f6b1717112c5.webp",980,1301]